{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-343473","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2026-08-11T12:03:41+00:00","discovered_at":"2026-08-11T12:05:00.311824+00:00","generated_at":"2026-08-11T12:05:05.907808+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Coya Q2 2026 net loss $6.6M; cash $43.2M funds ALS trial into 2H27","bullets":["Net loss $6.6M for Q2 2026 vs $6.1M in Q2 2025; R&D up $1.3M to $5.0M on COYA 302 ALS trial costs.","Cash and equivalents $43.2M at June 30, 2026, expected to fund operations past Phase 2 ALSTARS readout into 2H 2027.","FDA granted Fast Track Designation for COYA 302 in ALS; first cohort advanced into 24-week blinded active treatment extension.","Collaboration revenue flat at $0.2M under DRL agreement; G&A down $0.6M to $2.3M.","On track to complete ALSTARS enrollment in 2H 2026 and report topline data in Q1 2027; Phase 2 FTD study to initiate in 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-343473","json":"https://secwatch.observer/filing/0001193125-26-343473.json","markdown":"https://secwatch.observer/filing/0001193125-26-343473.md","text":"https://secwatch.observer/filing/0001193125-26-343473.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000119312526343473/0001193125-26-343473-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000119312526343473/coya-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T12:05:05.907808+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}